Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: Plasma metabolomics analysis

BMC Medicine

Volumn 10, Issue , 2012, Pages

  Zhao, Yue ^a,b,c   Fu, Li ^a,b,c   Li, Rong ^a,b,c   Wang, Li Na ^a,b   Yang, Yan ^a,b   Liu, Na Na ^a,c   Zhang, Chun Mei ^a,c   Wang, Ying ^a,c   Liu, Ping ^a,b   Tu, Bin Bin ^a,b   Zhang, Xue ^a,c   Qiao, Jie ^a,b,c  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology   (China)

Author keywords

amino acid metabolism; carbohydrate and lipid metabolism; inflammation; insulin resistance; polycystic ovary syndrome

Indexed keywords

ALANINE; AMINO ACID; CARBOHYDRATE; GLUCOSE; GLYCINE; HIGH DENSITY LIPOPROTEIN; LACTIC ACID; LIPID; LONG CHAIN FATTY ACID; ORNITHINE; PHENYLALANINE; PHOSPHATIDYLCHOLINE; PROLINE; SERINE; THREONINE; TRIACYLGLYCEROL; TRYPTOPHAN; TYROSINE; VALINE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AMINO ACID METABOLISM; ARTICLE; CARBOHYDRATE METABOLISM; CITRIC ACID CYCLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GAS CHROMATOGRAPHY; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; METABOLOMICS; OBESITY; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; RISK ASSESSMENT; SEMEN ANALYSIS; TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; FEMALE; HUMANS; METABOLOME; METABOLOMICS; PHENOTYPE; POLYCYSTIC OVARY SYNDROME;

EID: 84870232648     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-10-153     Document Type: Article

References (37)

1. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011, 7:219-231. 10.1038/nrendo.2010.217, 21263450.
2. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007, 370:685-697. 10.1016/S0140-6736(07)61345-2, 17720020.
3. Rizzo M, Berneis K, Spinas G, Rini GB, Carmina E. Long-term consequences of polycystic ovary syndrome on cardiovascular risk. Fertil Steril 2009, 91:1563-1567. 10.1016/j.fertnstert.2008.09.070, 18976752.
4. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010, 16:347-363. 10.1093/humupd/dmq001, 20159883.
5. Hughes C, Elgasim M, Layfield R, Atiomo W. Genomic and post-genomic approaches to polycystic ovary syndrome--progress so far: Mini Review. Hum Reprod 2006, 21:2766-2775. 10.1093/humrep/del222, 16936300.
6. Diamanti-Kandarakis E, Piperi C, Spina J, Argyrakopoulou G, Papanastasiou L, Bergiele A, Panidis D. Polycystic ovary syndrome: the influence of environmental and genetic factors. Hormones (Athens) 2006, 5:17-34.
7. Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Exp Rev Mol Med 2008, 10:e3.
8. Mukherjee S, Maitra A. Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome. Indian J Med Res 2010, 131:743-760.
9. Azziz R. Polycystic ovary syndrome, insulin resistance, and molecular defects of insulin signaling. J Clin Endocrinol Metab 2002, 87:4085-4087. 10.1210/jc.2002-021131, 12213851.
10. Giallauria F, Orio F, Palomba S, Lombardi G, Colao A, Vigorito C. Cardiovascular risk in women with polycystic ovary syndrome. J Cardiovasc Med (Hagerstown) 2008, 9:987-992.
11. Wang ET, Calderon-Margalit R, Cedars MI, Daviglus ML, Merkin SS, Schreiner PJ, Sternfeld B, Wellons M, Schwartz SM, Lewis CE, Williams OD, Siscovick DS, Bibbins-Domingo K. Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia. Obstet Gynecol 2011, 117:6-13. 10.1097/AOG.0b013e31820209bb, 3060760, 21173640.
12. Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab 2006, 91:786-789.
13. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81:19-25. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.
14. Wishart DS. Metabolomics: the principles and potential applications to transplantation. Am J Transplant 2005, 5:2814-2820. 10.1111/j.1600-6143.2005.01119.x, 16302993.
15. Lenz EM, Wilson ID. Analytical strategies in metabonomics. J Proteome Res 2007, 6:443-458. 10.1021/pr0605217, 17269702.
16. Wu Q, Zhang Q, Sun B, Yan X, Tang Y, Qiao X, Chen Q, Yu S, Liang F. 1H NMR-based metabonomic study on the metabolic changes in the plasma of patients with functional dyspepsia and the effect of acupuncture. J Pharm Biomed Anal 2010, 51:698-704. 10.1016/j.jpba.2009.09.042, 19854601.
17. Feng B, Wu S, Lv S, Liu F, Chen H, Yan X, Li Y, Dong F, Wei L. Metabolic profiling analysis of a d-galactosamine/lipopolysaccharide-induced mouse model of fulminant hepatic failure. J Proteome Res 2007, 6:2161-2167. 10.1021/pr0606326, 17497905.
18. Yang Y, Qiao J, Li R, Li MZ. Is interleukin-18 associated with polycystic ovary syndrome?. Reprod Biol Endocrinol 2011, 9:7. 10.1186/1477-7827-9-7, 3035581, 21244650.
19. Sun L, Hu W, Liu Q, Hao Q, Mao S, Sun B, Zhang Q, Qiao J, Yan X. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. J Proteome Res 2012, 11:2937-2946. 10.1021/pr3000317, 22428626.
20. Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011, 95:1073-1079. 10.1016/j.fertnstert.2010.12.027, 21247558.
21. Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 2001, 54:447-453.
22. Marei WF, Wathes DC, Fouladi-Nashta AA. Impact of linoleic acid on bovine oocyte maturation and embryo development. Reproduction 2010, 139:979-988. 10.1530/REP-09-0503, 20215338.
23. Toborek M, Lee YW, Garrido R, Kaiser S, Hennig B. Unsaturated fatty acids selectively induce an inflammatory environment in human endothelial cells. Am J Clin Nutr 2002, 75:119-125.
24. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WJ, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009, 9:311-326. 10.1016/j.cmet.2009.02.002, 19356713.
25. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Flore JC, Souza A, Melander O, Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. Nat Med 2011, 17:448-453. 10.1038/nm.2307, 3126616, 21423183.
26. Wurtz P, Tiainen M, Makinen VP, Kangas AJ, Soininen P, Saltevo J, Keinanen-Kiukaanniemi S, Mantyselka P, Lehtimaki T, Laakso M, Jula A, Kahonen M, Vanhala M, Ala-Korpela M. Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care 2012, 35:1749-1756. 10.2337/dc11-1838, 22563043.
27. Garcia-Macedo R, Sanchez-Munoz F, Almanza-Perez JC, Duran-Reyes G, Alarcon-Aguilar F, Cruz M. Glycine increases mRNA adiponectin and diminishes pro-inflammatory adipokines expression in 3T3-L1 cells. Eur J Pharmacol 2008, 587:317-321. 10.1016/j.ejphar.2008.03.051, 18499099.
28. Toulis KA, Goulis DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC, Papadimas I, Panidis D. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update 2009, 15:297-307. 10.1093/humupd/dmp006, 19261627.
29. Li F, Yin Y, Tan B, Kong X, Wu G. Leucine nutrition in animals and humans: mTOR signaling and beyond. Amino Acids 2011, 41:1185-1193. 10.1007/s00726-011-0983-2, 21773813.
30. Macotela Y, Emanuelli B, Bang AM, Espinoza DO, Boucher J, Beebe K, Gall W, Kahn CR. Dietary leucine--an environmental modifier of insulin resistance acting on multiple levels of metabolism. PLoS One 2011, 6:e21187. 10.1371/journal.pone.0021187, 3120846, 21731668.
31. Chand AL, Legge M. Amino acid transport system L activity in developing mouse ovarian follicles. Hum Reprod 2011, 26:3102-3108. 10.1093/humrep/der298, 21914669.
32. Guastella E, Longo RA, Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril 2010, 94:2197-2201. 10.1016/j.fertnstert.2010.02.014, 20303485.
33. Panidis D, Tziomalos K, Misichronis G, Papadakis E, Betsas G, Katsikis I, Macut D. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod 2012, 27:541-549. 10.1093/humrep/der418, 22144419.
34. Carmina E, Guastella E, Longo RA, Rini GB, Lobo RA. Correlates of increased lean muscle mass in women with polycystic ovary syndrome. Eur J Endocrinol 2009, 161:583-589. 10.1530/EJE-09-0398, 19605540.
35. Escobar-Morreale HF, Samino S, Insenser M, Vinaixa M, Luque-Ramirez M, Lasuncion MA, Correig X. Metabolic heterogeneity in polycystic ovary syndrome is determined by obesity: plasma metabolomic approach using GC-MS. Clin Chem 2012, 58:999-1009. 10.1373/clinchem.2011.176396, 22427353.
36. Chen MJ, Chiu HM, Chen CL, Yang WS, Yang YS, Ho HN. Hyperandrogenemia is independently associated with elevated alanine aminotransferase activity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2010, 95:3332-3341. 10.1210/jc.2009-2698, 20427499.
37. Diao FY, Xu M, Hu Y, Li J, Xu Z, Lin M, Wang L, Zhou Y, Zhou Z, Liu J, Sha J. The molecular characteristics of polycystic ovary syndrome (PCOS) ovary defined by human ovary cDNA microarray. J Mol Endocrinol 2004, 33:59-72. 10.1677/jme.0.0330059, 15291743.